Home › Non-Small Cell Lung Cancer › NCT04913311

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy

Who can join

All ages · All sexes

Inclusion Criteria:

* Newly-diagnosed NSCLC patients who will be undergoing concurrent chemotherapy and radiotherapy (XRT) followed by immune checkpoint inhibitors (CPI) therapy with durvalumab, as per the PACIFIC trial
* Willing to undergo all treatment and evaluation at MD Anderson Cancer Center (MDACC)
* Has access to a smartphone with the ability to transmit data via wireless connection or through their personal cellular plan
* Able and willing to perform home spirometry (HS) weekly without absolute contraindications to performing spirometry

About the study

This study looks at the side effects of chemotherapy and radiation (chemoradiation) followed by immunotherapy in patients with non-small cell lung cancer, with a particular focus on lung inflammation (pneumonitis). By collecting blood, stool and saliva samples, and data from lung function tests, researchers may be able to create a database of information about treatment and side effects in patients with non-small cell lung cancer who are receiving chemoradiation followed by immunotherapy. The information gained from this study may also help researchers find signs of problems with lung function earlier rather than later, since lung function is checked more often than routine care. This may improve how quickly these issues can be treated, and future patients may benefit from what is learned.

What is being tested

• Biospecimen Collection (procedure)
• Bronchoscopy with Bronchoalveolar Lavage (procedure)
• Chemoradiotherapy (other)
• Computed Tomography (procedure)
• Diagnostic Laboratory Biomarker Analysis (other)
• Immune Checkpoint Inhibitor (drug)

Sponsor: M.D. Anderson Cancer Center · Participants: 150 · Started: Jan 21, 2021

Contact the study team

Official record on ClinicalTrials.gov — NCT04913311

Locations in the U.S.

Conditions

• Non-Small Cell Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.